The Cost-Effectiveness of Brentuximab Vedotin As Consolidation Treatment After Autologous Stem-Cell Transplantation in Patients With Hodgkin Lymphoma and Increased Risk of Relapse
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.223
https://www.valueinhealthjournal.com/article/S1098-3015(17)30557-0/fulltext
Title :
The Cost-Effectiveness of Brentuximab Vedotin As Consolidation Treatment After Autologous Stem-Cell Transplantation in Patients With Hodgkin Lymphoma and Increased Risk of Relapse
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30557-0&doi=10.1016/j.jval.2017.08.223
First page :
A437
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
203